SCHEMBL2664533

SCHEMBL2664533

CCOC(=O)c1cnc(NC(=O)c2ccccc2)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.67
TSHR P16473 1/20 0.67
SMN1; SMN2 Q16637 8/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
HTT P42858 2/20 0.57
LCK P06239 1/20 0.57
KDR P35968 1/20 0.56
CCNE1 P24864 1/20 0.55
CDK2 P24941 1/20 0.55
CDK5 Q00535 1/20 0.55
GAA P10253 1/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
MAPT P10636 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
TP53 P04637 2/20 0.54
SCD O00767 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580537 0.87 KDR (0.61) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL5657957 0.86 NPSR1 (0.53) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL12309919 0.86 NPC1 (0.66) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL2664848 0.85 GCK (0.53) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL23742116 0.84 ALDH1A1 (0.52) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL28426737 0.83 CA1 (0.54) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL22510117 0.82 ALDH1A1 (0.46) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL4756065 0.81 SMN1; SMN2 (0.50) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL22510080 0.81 TP53 (0.55) ALDH1A1RAB9AKDM4EHPGDMAPT
SCHEMBL29074237 0.81 NSUN3 (0.60) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 ALDH1A1 1137/4885TSHR 2316/4885SMN1; SMN2 1886/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 ALDH1A1 1137/4885TSHR 2316/4885SMN1; SMN2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.